In Case You Missed It
5 Things You Must Know Before the Market Opens
Jim Cramer's Daily Booyah
Winners & Losers
Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.
I believe this president goes full Trumpian tonight, in a style that he has made all his own.
The pharmaceutical distributor is finally turning around.
It used the earning's call to pass much of the blame for high drug prices onto pharmaceutical companies.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.